Aethlon Medical to merge with North Immunology to advance NOR-101
North Immunology’s lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody for atopic dermatitis, targeting both type 2 and non-type 2 inflammation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.